225 related articles for article (PubMed ID: 22371126)
1. In the cystoscopic follow-up of non-muscle-invasive transitional cell carcinoma, NMP-22 works for high grades, but unreliable in low grades and upper urinary tract tumors.
Coskuner E; Cevik I; Ozkan A; Dillioglugil O; Akdas A
Int Urol Nephrol; 2012 Jun; 44(3):793-8. PubMed ID: 22371126
[TBL] [Abstract][Full Text] [Related]
2. [Non-invasive urine tests in diagnosis and as prognostic markers for urinary bladder carcinoma. Comparison of the BTAstat and NMP 22 tests with immunocytology using monoclonal antibodies against Lewis X and 486p3/12].
Friedrich MG; Hellstern A; Hautmann SH; Noldus I; Huland H
Urologe A; 2003 Apr; 42(4):523-30. PubMed ID: 12715124
[TBL] [Abstract][Full Text] [Related]
3. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma.
Raman JD; Sosa RE; Vaughan ED; Scherr DS
Urology; 2007 Feb; 69(2):251-4. PubMed ID: 17320658
[TBL] [Abstract][Full Text] [Related]
4. Nuclear matrix protein 22 as adjunct to urine cytology and cystoscopy in follow-up of superficial TCC of urinary bladder.
Gupta NP; Sharma N; Kumar R
Urology; 2009 Mar; 73(3):592-6; discussion 596-7. PubMed ID: 19168205
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic value of voided urine and bladder barbotage cytology in detecting transitional cell carcinoma of the urinary tract.
Konety BR; Metro MJ; Melham MF; Salup RR
Urol Int; 1999; 62(1):26-30. PubMed ID: 10436427
[TBL] [Abstract][Full Text] [Related]
6. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment.
Soloway MS; Briggman V; Carpinito GA; Chodak GW; Church PA; Lamm DL; Lange P; Messing E; Pasciak RM; Reservitz GB; Rukstalis DB; Sarosdy MF; Stadler WM; Thiel RP; Hayden CL
J Urol; 1996 Aug; 156(2 Pt 1):363-7. PubMed ID: 8683680
[TBL] [Abstract][Full Text] [Related]
7. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer?
Wiener HG; Mian C; Haitel A; Pycha A; Schatzl G; Marberger M
J Urol; 1998 Jun; 159(6):1876-80. PubMed ID: 9598479
[TBL] [Abstract][Full Text] [Related]
8. NMP22 in transitional cell carcinoma of the urinary bladder.
Su CK; Yang CR; Horng YY; Kao YL; Ho HC; Ou YC; Cheng CL
J Chin Med Assoc; 2003 May; 66(5):294-8. PubMed ID: 12908572
[TBL] [Abstract][Full Text] [Related]
9. Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder.
Sawczuk IS; Bagiella E; Sawczuk AT; Yun EJ
Cancer Detect Prev; 2000; 24(4):364-8. PubMed ID: 11059567
[TBL] [Abstract][Full Text] [Related]
10. The development of bladder tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma of the upper urinary tract.
Kang CH; Yu TJ; Hsieh HH; Yang JW; Shu K; Huang CC; Chiang PH; Shiue YL
Cancer; 2003 Oct; 98(8):1620-6. PubMed ID: 14534877
[TBL] [Abstract][Full Text] [Related]
11. [Tumor markers for bladder cancer: up-to-date study by the Kiel Tumor Bank].
Hautmann S; Eggers J; Meyhoff H; Melchior D; Munk A; Hamann M; Naumann M; Braun PM; Jünemann KP
Urologe A; 2007 Nov; 46(11):1508-13. PubMed ID: 17932643
[TBL] [Abstract][Full Text] [Related]
12. Combinations of urine-based tumour markers in bladder cancer surveillance.
Horstmann M; Patschan O; Hennenlotter J; Senger E; Feil G; Stenzl A
Scand J Urol Nephrol; 2009; 43(6):461-6. PubMed ID: 19903092
[TBL] [Abstract][Full Text] [Related]
13. Voided urinary cytology in bladder cancer: is it time to review the indications?
Talwar R; Sinha T; Karan SC; Doddamani D; Sandhu A; Sethi GS; Srivastava A; Narang V; Agarwal A; Adhlakha N
Urology; 2007 Aug; 70(2):267-71. PubMed ID: 17826487
[TBL] [Abstract][Full Text] [Related]
14. [Determination of NMP-22 as recurrence marker in bladder cancer. Preliminary study].
Pérez García FJ; Escaf Barmadah S; Fernández Gómez JM; Rodríguez Martínez JJ; Martín Benito JL
Arch Esp Urol; 2000 May; 53(4):305-12. PubMed ID: 10900760
[TBL] [Abstract][Full Text] [Related]
15. Comparative study of NMP-22, telomerase, and BTA in the detection of bladder cancer.
Abd El Gawad IA; Moussa HS; Nasr MI; El Gemae EH; Masooud AM; Ibrahim IK; El Hifnawy NM
J Egypt Natl Canc Inst; 2005 Sep; 17(3):193-202. PubMed ID: 16799657
[TBL] [Abstract][Full Text] [Related]
16. A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results.
Poulakis V; Witzsch U; De Vries R; Altmannsberger HM; Manyak MJ; Becht E
BJU Int; 2001 Nov; 88(7):692-701. PubMed ID: 11890239
[TBL] [Abstract][Full Text] [Related]
17. Urinary dosage of nuclear matrix protein 22 (NMP22) like biologic marker of transitional cell carcinoma (TCC): a study on patients with hematuria.
Paoluzzi M; Cuttano MG; Mugnaini P; Salsano F; Giannotti P
Arch Ital Urol Androl; 1999 Feb; 71(1):13-8. PubMed ID: 10193018
[TBL] [Abstract][Full Text] [Related]
18. Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology.
Shariat SF; Casella R; Wians FH; Ashfaq R; Balko J; Sulser T; Gasser TC; Sagalowsky AI
Eur Urol; 2004 Mar; 45(3):304-13; author reply 313. PubMed ID: 15036675
[TBL] [Abstract][Full Text] [Related]
19. Testing for urinary hyaluronate improves detection and grading of transitional cell carcinoma.
Passerotti CC; Srougi M; Bomfim AC; Martins JR; Leite KR; Dos Reis ST; Sampaio LO; Ortiz V; Dietrich CP; Nader HB
Urol Oncol; 2011; 29(6):710-5. PubMed ID: 19962919
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the nuclear matrix protein 22 with voided urine cytology in the diagnosis of transitional cell carcinoma of the bladder.
Lekili M; Sener E; Demir MA; Temeltaş G; Müezzinoğlu T; Büyüksu C
Urol Res; 2004 May; 32(2):124-8. PubMed ID: 14685796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
